The treatment, Inmazeb, is a combination of three genetically-engineered antibodies. The company Regeneron Pharmaceuticals developed it to treat both young and old patients with the version of virus known as Zaire Ebola. It is the deadliest of all four versions of Ebola virus known to infect humans.